Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating

05/06/2022 | 11:24am EDT


© MT Newswires 2022
All news about ZAI LAB LIMITED
09/21Asian ADRs Move Lower in Wednesday Trading
MT
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
GL
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
AQ
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® Maintenance Treatment i..
CI
09/12DRI Healthcare Trust Acquires Royalty Interest in Zejula, Currently Approved for Treatm..
MT
09/09Asian ADRs Climb Sharply Higher in Friday Trading
MT
09/08Transcript : Zai Lab Limited Presents at Citi's 17th Annual BioPharma Confere..
CI
08/29US, China Reach Audit Deal to Prevent Delistings
MT
08/26Zai Lab : Updated Statement on SEC Listing Matter
PU
08/23Zai Lab Announces Participation in September Investor Conferences
GL
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 222 M - -
Net income 2022 -468 M - -
Net cash 2022 799 M - -
P/E ratio 2022 -8,24x
Yield 2022 -
Capitalization 3 546 M 3 546 M -
EV / Sales 2022 12,4x
EV / Sales 2023 6,31x
Nbr of Employees 1 951
Free-Float 99,8%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 37,00 $
Average target price 97,22 $
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-41.13%3 546
CSL LIMITED-4.33%87 783
SAMSUNG BIOLOGICS CO.,LTD.-16.06%38 653
BIOGEN INC.-17.56%28 700
WUXI BIOLOGICS (CAYMAN) INC.-49.86%25 210
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-33.88%19 085